Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive data from a 12-week Phase 2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback